On the heels of a strong earnings report and more than double the average volume, shares of Microsoft (MSFT) soared by nearly five percent on Friday and have positioned the stock as one to watch during the coming week following the exciting close of Friday.
Although some analysts predicted a week quarter for McDonald's (MCD), the company surprised and posted solid results, also a factor in Friday's strong showing for the markets. The same can be said for General Electric (GE), whose numbers beat the general consensus, although revenue was down.
Those three key players will be all but forgotten next week, however, when a slew of new earnings reports will dominate the headlines making last week's players over-the-hill, old news.
All eyes are going to be on Apple (AAPL) during the coming week, with the tech behemoth set to report earnings on Tuesday afternoon. Although AAPL shares have been on the slide over the past couple of weeks, dropping a good ten percent during that time frame, most predict another quarter of huge growth that could once again propel shares to over the six hundred dollar mark. There are naysayers, though, that believe the best days of Apple may already be in the rear view mirror, even with the prospects of Apple TV set to hit the markets later this year.
Whatever this company brings to the table on Tuesday will most likely dictate the sentiment of trading on Wednesday morning.
It could be that Apple is THE story to watch during the coming week.
Synergy Pharmaceuticals (SGYP): The strongest-volumed day in a couple of weeks supported a two percent price increase on Friday for shares of Synergy Pharmaceuticals (SGYP), a company that has been gaining increasingly positive coverage from analysts over the past couple of months.
Last week's modest move higher saw SGYP shares trading at levels not seen since early March.
Given that the halfway point has just recently been met for enrollment in an ongoing Phase II/III trial for lead product candidate, Plecanatide, which would enter into a multi-billion dollar market if approved, interest could start increasing in the company which may enable the share price to approach the enthusiastic estimates of analysts.
Summer Street has initiated coverage with a price target of $9, Brean Murray's most recent rating is accompanied by a price tag of $13, and just a couple of weeks ago Roth Capital threw its own prediction into the mix with a price target of $12.
For full version of this week's Weekly Stock Watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-april-23-27-hgsi-cpst-aapl-mcd-ge-msft-sgyp-irwd-gern-actc-amrn-ttnp-dis-imuc-ctso-siga-sppi-bdsi
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
Follow VFC's Stock House on Twitter: http://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.